為達最佳瀏覽效果,建議使用 Chrome、Firefox 或 Microsoft Edge 的瀏覽器。

請至Edge官網下載 請至FireFox官網下載 請至Google官網下載
晴時多雲

限制級
您即將進入之新聞內容 需滿18歲 方可瀏覽。
根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定,已於網站首頁或各該限制級網頁,依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會(TICRF)網站:http://www.ticrf.org.tw

《TAIPEI TIMES》NHRI screening kits expected by year end

An Adimmune Corp employee holds test samples of a vaccine in development for COVID-19 in an undated photograph.

Photo courtesy of Adimmune Corp

An Adimmune Corp employee holds test samples of a vaccine in development for COVID-19 in an undated photograph. Photo courtesy of Adimmune Corp

2020/03/14 03:00

VACCINE DEVELOPMENT: The institute’s president said it is focusing on peptide vaccines, but would also develop recombinant vector, DNA and subunit vaccines

/ Staff writer, with CNA

Rapid screening kits being developed by the National Health Research Institute (NHRI) for COVID-19 could be available by the end of the year, NHRI president Liang Kung-yee (梁賡義) said on Wednesday.

The institute is testing the virus identification capacity of antibodies that were selected for the development of the kits, Liang said, adding that the testing is expected to be completed by March 31.

The subsequent steps are to conduct technology transfers to companies and undertake clinical trials with human tissue, Liang said.

The kits, like those that are used for influenza, would not be 100 percent accurate, he said.

Nevertheless, they are a “vital step” for public health, he said.

The state-run institute is using antibodies for SARS, which was a major outbreak in Taiwan in 2003, as the basis for its development of the kits to test for COVID-19, which has spread rapidly worldwide since it emerged in the Chinese city of Wuhan late last year.

Academia Sinica is also developing COVID-19 rapid screening kits.

Asked about progress on development of a vaccine, Liang said that the institute is focusing on peptide vaccines, but would also develop other types, such as recombinant vector, DNA and subunit vaccines.

The NHRI hopes to determine the best candidate vaccine by early June, after which it would start toxicology studies and animal experiments, he said.

After the Food and Drug Administration approves clinical trials, the NHRI would proceed with them, which, due to safety reasons, is expected to take at least one year, he said.

The WHO on March 4 released a Draft Landscape of COVID-19 Candidate Vaccines, which listed 35 projects in development, but did not include the Taiwanese efforts.

新聞來源:TAIPEI TIMES

不用抽 不用搶 現在用APP看新聞 保證天天中獎  點我下載APP  按我看活動辦法

焦點今日熱門
看更多!請加入自由時報粉絲團

網友回應

載入中
此網頁已閒置超過5分鐘,請點擊透明黑底或右下角 X 鈕。